# EDGAR Filing Document

**Accession Number:** 0001933414
**File Stem:** 0001628280-23-003008
**Filing Date:** 2023-2
**Character Count:** 12467
**Document Hash:** 0a67527b8d27a5fd21638d8d62f99dec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-003008.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001628280-23-003008

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**EFFECTIVENESS DATE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269672
- **FILM NUMBER:** 23607462

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

**As filed with the Securities and Exchange Commission on February 9, 2023**

**Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-1** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

**Mineralys Therapeutics, Inc.**

**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **84-1966887** |
| **(State or Other Jurisdiction of<br>Incorporation or Organization)** | **(Primary Standard Industrial<br>Classification Code Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**150 N. Radnor Chester Road, Suite F200**

**Radnor, PA 19087**

**(888) 378-6240** 

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)** 

**Jon Congleton**

**Chief Executive Officer** 

**Mineralys Therapeutics, Inc.**

**150 N. Radnor Chester Road, Suite F200**

**Radnor, PA 19087**

**(888) 378-6240** 

**(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)** 

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Cheston J. Larson**<br>**Matthew T. Bush**<br>**Latham & Watkins LLP**<br>**12670 High Bluff Drive**<br>**San Diego, California 92130**<br>**(858) 523-5400** | **Adam Levy**<br>**Chief Financial Officer and Chief Business Officer**<br>**Mineralys Therapeutics, Inc.**<br>**150 N. Radnor Chester Road, Suite F200**<br>**Radnor, PA 19087**<br>**(888) 378-6240**  | **Ilir Mujalovic**<br>**Shearman & Sterling LLP**<br>**559 Lexington Avenue**<br>**New York, NY 10022**<br>**(212) 848-4000** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-269282)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definition of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This Registration Statement on Form S-1 (this "Registration Statement") is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the sole purpose of increasing the aggregate number of shares of common stock offered by Mineralys Therapeutics, Inc. (the "Registrant") by 2,300,000 shares, 300,000 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Filing Fee Table (Exhibit 107) filed as an exhibit to the Registration Statement on Form S-1, as amended (File No. 333-269282) (the "Prior Registration Statement"). The information set forth in the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference in this filing.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

------

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| 5.1 | <u>[Opinion of Latham & Watkins LLP (incorporated by reference to Exhibit 5.1 filed with the Prior Registration Statement on February 2, 2023)](https://www.sec.gov/Archives/edgar/data/1933414/000162828023001963/exhibit51-sx1a1.htm)</u> |
| 23.1 | <u>[Consent of Ernst & Young LLP, independent registered public accounting firm](exhibit231-sx1mef.htm)</u> |
| 23.2 | <u>[Consent of Latham & Watkins LLP (included in Exhibit 5.1)](https://www.sec.gov/Archives/edgar/data/1933414/000162828023001963/exhibit51-sx1a1.htm)</u> |
| 24.1 | <u>[Power of Attorney (included on the signature page of the Prior Registration Statement filed on January 18, 2023)](https://www.sec.gov/Archives/edgar/data/1933414/000162828023001171/mineralys-sx1.htm#id02d313eb072450e8967d58e6e5213a1_65)</u> |
| 107 | <u>[Filing Fee Table](exhibit107-sx1mef.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Radnor, State of Pennsylvania, on this 9th day of February, 2023.

---

| | |
|:---|:---|
| **MINERALYS THERAPEUTICS, INC.** | **MINERALYS THERAPEUTICS, INC.** |
| By: | /s/ Jon Congleton |
|  | Jon Congleton |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jon Congleton | Chief Executive Officer<br>(principal executive officer) | February 9, 2023 |
| Jon Congleton | Chief Executive Officer<br>(principal executive officer) | February 9, 2023 |
| /s/ Adam Levy | Chief Financial Officer<br>(principal financial and accounting officer) | February 9, 2023 |
| Adam Levy | Chief Financial Officer<br>(principal financial and accounting officer) | February 9, 2023 |
| \* | Executive Chairman | February 9, 2023 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | Executive Chairman | February 9, 2023 |
| \* | Director | February 9, 2023 |
| Srinivas Akkaraju, M.D., Ph.D. | Director | February 9, 2023 |
| \* | Director | February 9, 2023 |
| Alexander Asam, Ph.D. | Director | February 9, 2023 |
| \* | Director | February 9, 2023 |
| Derek DiRocco, Ph.D. | Director | February 9, 2023 |
| \* | Director | February 9, 2023 |
| Olivier Litzka, Ph.D. | Director | February 9, 2023 |
| \* | Director | February 9, 2023 |
| Takeshi Takahashi, M.B.A. | Director | February 9, 2023 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Jon Congleton |
|  | Jon Congleton |
|  | Attorney-in-fact |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table** 

**Form S-1**

**Mineralys Therapeutics, Inc.**

<u>Table 1 - Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br>**Type** | **Security**<br>**Class Title** | **Fee Calculation**<br>**Rule** | **Amount**<br>**Registered**<sup>(1)(2)</sup> | **Proposed Maximum Offering Price Per Share** | **Maximum** <br>**Aggregate** <br>**Offering Price**<sup>(3)</sup> | **Fee Rate** | **Amount** <br>**of Registration Fee** |
| Equity | Common Stock, par value $0.0001 per share | Rule 457(a) | 2300000 | $16.00 | $36800000 | 0.00011020 | $4056 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** |  |  | $36800000 | 0.00011020 | $4056 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Previously Paid** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Previously Paid** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Previously Paid** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fees Offsets** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  |  |  | $4056 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>&nbsp;&nbsp;&nbsp;&nbsp;The registrant previously registered securities with a proposed maximum aggregate offering price not to exceed $184,000,000 on a Registration Statement on Form S-1 (File No. 333-269282), which was declared effective by the Securities and Exchange Commission on February 9, 2023. In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $36,800,000 is hereby registered, which includes the shares of common stock that the underwriters have the option to purchase.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup>&nbsp;&nbsp;&nbsp;&nbsp;Includes 300,000 shares of common stock that the underwriters have the option to purchase.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(3)</sup>&nbsp;&nbsp;&nbsp;&nbsp;Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(a) under the Securities Act of 1933, as amended.

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-1 MEF) filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated October 12, 2022 (except for Note 1, as to which the date is February 2, 2023), with respect to the financial statements of Mineralys Therapeutics, Inc. included in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-269282) and related prospectus of Mineralys Therapeutics, Inc. for the registration of its common stock.

---

| |
|:---|
| /s/Ernst & Young LLP |
| Denver, Colorado |
| February 9, 2023 |

---

<br>